Welcome to our dedicated page for Talphera SEC filings (Ticker: tlph), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vRosalind Advisors and affiliates have filed an amended Schedule 13G reporting a sizable passive stake in Talphera, Inc. common shares. Rosalind Advisors Inc., Rosalind Master Fund L.P., and portfolio managers Steven Salamon and Gilad Aharon report beneficial ownership of 13,150,954 Talphera common shares, representing 9.9% of the class based on 46,609,618 shares outstanding as of November 5, 2025.
The position consists of 3,579,273 common shares plus additional shares issuable from warrants and pre‑funded warrants, some of which are subject to a 9.99% ownership blocker. The reporting persons certify the holdings are in the ordinary course of business and not for the purpose of influencing control.
Talphera, Inc. received an updated ownership disclosure showing that AIGH Capital Management LLC, AIGH Investment Partners LLC, and Orin Hirschman together beneficially own 4,661,502 shares of Talphera common stock, representing 9.8% of the outstanding class as of the event date.
The filing notes rights to purchase an additional 5,454,545 common shares in a second closing, but these are not currently exercisable because of beneficial ownership limits. The reporting persons state the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Talphera.
Talphera, Inc. filed a preliminary S-3 prospectus registering the resale by selling stockholders of up to 1,023,890 shares of common stock and up to 1,706,484 shares issuable upon exercise of pre-funded warrants. The company is not selling any securities in this offering.
Talphera will not receive proceeds from sales by the selling stockholders; they will receive all sale proceeds, while Talphera covers registration expenses. The shares may be sold in public or private transactions at market or negotiated prices. The last reported sale price of TLPH was $1.26 on October 27, 2025.
Shares outstanding were 46,609,618 as of October 25, 2025; this is a baseline figure, not the amount being offered.
Talphera, Inc. (TLPH) filed a Form S-8 registering 1,400,000 additional shares of common stock for its Amended and Restated 2020 Equity Incentive Plan and 100,000 additional shares for its Amended and Restated 2011 Employee Stock Purchase Plan. The filing uses General Instruction E to incorporate prior S‑8 registrations by reference, streamlining the addition to the company’s existing employee equity programs.
The registration relates to shares issuable under established compensation plans and includes standard exhibits and consents. The filing was signed by Chief Executive Officer Vincent J. Angotti, with the company’s CFO designated as agent for service.
Talphera (TLPH) disclosed a director equity grant on Form 4. On 10/23/2025, the reporting person received 4,267 restricted stock units, each representing one share of common stock. The RSUs vest 100% on the first anniversary of the grant date, contingent on continuous service.
On the same date, the director was granted a stock option for 25,600 shares at an exercise price of $1.14, expiring on 10/22/2035, with 100% vesting after one year. Following these transactions, the director beneficially owned 8,859 common shares, held directly.
Talphera (TLPH) filed a Form 4 disclosing equity grants to a director. On 10/23/2025, the reporting person received 4,267 restricted stock units at $0 and a stock option for 25,600 shares at an exercise price of $1.14. The RSUs and the options each vest 100% on the first anniversary of the grant date, subject to continuous service. Following these transactions, the reporting person held 8,859 shares directly and 25,600 derivative securities (options).
Talphera, Inc. (TLPH) reported an insider equity grant. A director received 4,267 restricted stock units on 10/23/2025, recorded at $0 per unit. Following the grant, the individual directly holds 9,047 shares of common stock.
The director was also granted a stock option for 25,600 shares at an exercise price of $1.14 per share, expiring on 10/22/2035. Both the RSUs and the option are scheduled to vest 100% on the one-year anniversary of the grant date, contingent on continuous service.
Talphera, Inc. (TLPH) reported a director equity grant on a Form 4. The filing shows 4,267 restricted stock units awarded at $0, and a stock option for 25,600 shares with a $1.14 exercise price. Both the RSUs and the option vest 100% on the one-year anniversary of the 10/23/2025 grant date, subject to continuous service. The option expires on 10/22/2035. Following the transaction, the director beneficially owned 8,547 shares of common stock directly.
Talphera (TLPH) reported a director equity grant. On 10/23/2025, the director acquired 4,267 shares of common stock via restricted stock units at $0 and received a stock option covering 25,600 shares at an exercise price of $1.14, expiring 10/22/2035.
The filing states the RSUs vest 100% on the first anniversary of the grant date, subject to continuous service. The option also vests 100% on the one-year anniversary under the same condition. Following the transactions, 17,609 common shares were beneficially owned directly, and 25,600 options were held.
Talphera (TLPH) reported a director equity grant on Form 4 dated 10/23/2025. The filing shows the acquisition of 4,267 shares of common stock at $0, reflecting restricted stock units that each convert into one share and vest 100% on the first anniversary of the grant date.
The director was also granted a stock option for 25,600 shares at an exercise price of $1.14, expiring on 10/22/2035, with 100% vesting on the one-year anniversary of the grant. Following these transactions, the director beneficially owned 7,312 common shares and 25,600 options.
FAQ
What is the current stock price of Talphera (tlph)?
What is the market cap of Talphera (tlph)?
